Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Elliquis

- PMLiVE

Pfizer beats earnings estimates as new products grow

Lyrica, Inlyta and Xalkori help offset generic competition

- PMLiVE

Blow to Pfizer as dacomitinib fails in lung cancer trials

Unable to demonstrate improved survival in patients

Bristol-Myers Squibb (BMS) building

BMS shares fall on nivolumab jitters despite solid Q4 results

Awaiting data from ongoing studies before advancing cancer prospect

- PMLiVE

ViiV wins European approval for Tivicay

HIV treatment licensed in combination with other anti-retroviral drugs

- PMLiVE

AZ gets green light in EU for Xigduo diabetes combination

Wins approval for first line extension of Forxiga

- PMLiVE

FDA clears BMS/AZ’s dapagliflozin at second attempt

Diabetes drug approved as companies look to end alliance

- PMLiVE

AstraZeneca buys BMS out of diabetes alliance

Will spend up to $4.3bn to secure sole rights to Onglyza and Forxiga

german flag

BMS and AZ pull diabetes drug in Germany

Unable to agree price with health authorities

- PMLiVE

BMS appoints leading oncologist to board

Thomas Lynch is director of Yale Cancer Center

Pfizer’s Jonathan Emms to be ABPI president

Will take over from MSD's Deepak Khanna in April

- PMLiVE

Pfizer ups the ante on clinical transparency

Revamps access to data portal

- PMLiVE

ViiV’s Tivicay for HIV on course for EU approval

More positive news for GSK, Pfizer and Shionogi joint venture

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links